Celyad Oncology SA
CLYYF
$0.65
-$0.03-4.41%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -6.30M | -7.35M | -8.39M | -8.78M | -9.14M |
| Total Depreciation and Amortization | 394.80K | 497.80K | 600.40K | 693.30K | 781.90K |
| Total Amortization of Deferred Charges | 92.00K | 84.90K | 76.80K | 76.80K | 76.80K |
| Total Other Non-Cash Items | -139.60K | 132.40K | 409.20K | -367.80K | -1.13M |
| Change in Net Operating Assets | -191.60K | -1.69M | -3.20M | -5.13M | -7.03M |
| Cash from Operations | -6.14M | -8.32M | -10.50M | -13.51M | -16.44M |
| Capital Expenditure | -- | -313.80K | -631.10K | -803.10K | -972.50K |
| Sale of Property, Plant, and Equipment | 16.20K | 22.20K | 28.10K | 743.80K | 1.45M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -127.50K | -128.00K | -128.50K | -83.50K | -37.70K |
| Cash from Investing | -111.30K | -419.70K | -731.60K | -142.90K | 438.50K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -167.00K | -151.50K | -136.00K | -140.50K | -145.00K |
| Issuance of Common Stock | -- | 4.75M | 9.49M | 9.49M | 9.49M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.15M | 2.71M | 2.28M | 1.14M | 10.00K |
| Cash from Financing | 3.23M | 7.89M | 12.59M | 11.36M | 10.13M |
| Foreign Exchange rate Adjustments | -4.30K | -2.20K | 0.00 | -500.00 | -1.00K |
| Miscellaneous Cash Flow Adjustments | 100.00 | -400.00 | -1.00K | -500.00 | -- |
| Net Change in Cash | -3.03M | -861.40K | 1.36M | -2.29M | -5.87M |